Vir Biotechnology, Inc.
San Francisco, California, United States · Biotechnology
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
Key facts
- Headquarters
- San Francisco, California, United States
- Employees
- 447
- Industries
- Biotechnology
- Status
- Public (VIR)
- Website
- vir.bio
- Company page
Recent activity at Vir Biotechnology, Inc.
- : Vir Biotechnology Appoints Dr. Suzanne Topalian as Class III Director
- : Vir Biotechnology Appoints David Liu as Chief Medical Officer
- : Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
- : SEC 8-K (1.01):
- : SEC 8-K (8.01): The filing reports significant findings from the ongoing Phase 3 ECLIPSE 1 clinical trial which were presented at the American Association for the Study of Liver Diseases on November 8, 2026. This trial involved 124 patients randomized to receive either the treatment combination of elebsiran and tobevibart or delayed treatment. The trial met its primary endpoint with 44% of patients achieving undetectable hepatitis delta virus (HDV) RNA after 48 weeks, compared to 0% in the delayed group (p<0.0001). Safety was also highlighted, with favorable outcomes and minimal adverse events reported, indicating the treatment regimen's tolerability and effectiveness in both cirrhotic and non-cirrhotic patients. This could have significant implications for the treatment of advanced HDV-related liver disease.
- : SEC 8-K (5.02): On October 26, 2026, Vir Biotechnology, Inc. increased the size of its Board of Directors from eight to nine members and appointed Suzanne Topalian, M.D. as a Class III director to fill the vacancy. This appointment is effective as of October 27, 2026, and Dr. Topalian will also serve on the Science and Technology Committee. She will receive standard compensation per the company's director compensation policy and was granted stock options and restricted stock units under the 2019 Equity Incentive Plan. The appointment signifies an expansion of the Board's expertise in scientific and technological matters, aligning with the company's strategic objectives leading up to the 2028 annual meeting of stockholders.
- : SEC 8-K (8.01): On October 14, 2026, Vir Bio announced through a press release that it entered into a significant agreement (the Agreement) and a Securities Purchase Agreement (SPA) with Gilead. The announcement outlines Vir Bio's intentions to collaborate on developing three novel PRO-XTEN® dual-masked TCE candidates targeting particular solid tumor-associated antigens. This strategic partnership is expected to bolster Vir Bio's financial and operational capabilities, with potential implications for future product development. The press release emphasizes key factors and risks associated with drug development, indicating the complex dynamics of this collaboration and the associated financial obligations.
- : SEC 8-K (8.01): On October 8, 2026, Vir Biotechnology, Inc. announced via a press release that the U.S. Food and Drug Administration granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager (TCE). This designation is for the treatment of late-line metastatic castration-resistant prostate cancer. The product is being co-developed with Astellas Pharma Inc. as part of a global strategic collaboration, highlighting its significance in the oncology therapeutic space.
- : SEC 8-K (5.02): On October 1, 2026, Vir Biotechnology, Inc. announced the appointment of Aziz Sawaf, MBEE, MBA, CFA as the Executive Vice President and Chief Financial Officer, with the effective date set for October 5, 2026. Following this change, Brent Sabatini, CPA, MBA, will stop serving as the interim principal financial officer but will remain as Senior Vice President and Chief Accounting Officer. This transition is significant for the company's financial leadership and could impact strategic financial decisions moving forward.
- : SEC 8-K (5.02): On July 20, 2026, Jason O’Byrne, the Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (Vir Bio), informed the company of his resignation, effective August 3, 2026, as he pursues another opportunity. His departure was not due to any disagreements regarding the company's operations or policies. Subsequently, on July 23, 2026, Brent Sabatini was appointed as the interim principal financial officer effective August 3, 2026. Mr. Sabatini brings over two decades of experience and has served as Vir Bio’s Senior Vice President and Chief Accounting Officer since February 2023. He will not receive any adjustment or additional compensation for his new role.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Vir Biotechnology, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| May 2020 | Venture | $32.4M |
| May 2020 | Venture | $250.0M |
| Jun 2018 | Venture | $66.0M |
Leadership
- George Scangos, Executive Officer, Director
- Vicki Sato, Director
- Robert More, Director
- Robert Nelsen, Director
- Dipchand Nishar, Director
- Robert Perez, Director
- Saira Ramasastry, Director
- Phillip Sharp, Director
Verified email and direct lines for Vir Biotechnology, Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Vir Biotechnology, Inc. files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Vir Biotechnology, Inc. in the news
- Vir Biotechnology Appoints David Liu as Chief Medical Officer - Business Wire (Oct 07, 2026)
- Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - PR Newswire (Feb 23, 2026)
- Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire (Aug 31, 2026)
- Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results - Business Wire (May 06, 2026)
- Vir Biotechnology Announces Chief Financial Officer Transition - Business Wire (Jul 24, 2026)
- Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer - Business Wire (Oct 01, 2026)
- Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference - Business Wire (Nov 02, 2026)
- Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer - Business Wire (Oct 08, 2026)
Companies similar to Vir Biotechnology, Inc.
- New Haven biotech firm · Biotechnology
- Medisca · Biotechnology
- Anika Therapeutics · Biotechnology
- Abzena · Biotechnology
- bluebird bio · Biotechnology
About Vir Biotechnology, Inc.: questions and answers
What does Vir Biotechnology, Inc. do?
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
Where is Vir Biotechnology, Inc. headquartered?
Vir Biotechnology, Inc. is headquartered in San Francisco, California, United States.
How many employees does Vir Biotechnology, Inc. have?
Vir Biotechnology, Inc. has about 447 employees.
Has Vir Biotechnology, Inc. raised funding?
Yes. Fundz has recorded 3 funding events for Vir Biotechnology, Inc.. The most recent, $32.4M, was in May 2020.
What is the latest news on Vir Biotechnology, Inc.?
On Oct 28, 2026, Vir Biotechnology Appoints Dr. Suzanne Topalian as Class III Director
Is Vir Biotechnology, Inc. a public company?
Yes. Vir Biotechnology, Inc. is publicly traded under the ticker VIR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy